EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 213 / Numéro 3-4 (2019) Biologie Aujourd’hui, 213 3-4 (2019) 109-120 References
Free Access
Issue
Biologie Aujourd’hui
Volume 213, Number 3-4, 2019
Page(s) 109 - 120
DOI https://doi.org/10.1051/jbio/2019025
Published online 12 décembre 2019
  • Abbasi Gharibkandi, N., Hosseinimehr, S.J. (2019). Radiotracers for imaging of Parkinson’s disease. Eur J Med Chem, 166, 75-89. [PubMed] [Google Scholar]
  • Ametamey, S.M., Honer, M., Schubiger, P.A. (2008). Molecular imaging with PET. Chem Rev, 108, 1501-1516. [CrossRef] [PubMed] [Google Scholar]
  • Backes, H., Walberer, M., Ladwig, A., Rueger, M.A., Neumaier, B., Endepols, H., Hoehn, M., Fink, G.R., Schroeter, M., Graf, R. (2016). Glucose consumption of inflammatory cells masks metabolic deficits in the brain. Neuroimage, 128, 54-62. [CrossRef] [PubMed] [Google Scholar]
  • Bakota, L., Brandt, R. (2016). Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs, 76, 301-313. [CrossRef] [PubMed] [Google Scholar]
  • Barron, H., Hafizi, S., Andreazza, A.C., Mizrahi, R. (2017). Neuroinflammation and oxidative stress in psychosis and psychosis risk. Int J Mol Sci, 18, 1-13. [Google Scholar]
  • Barros, L.F., Porras, O.H., Bittner, C.X. (2005). Why glucose transport in the brain matters for PET. Trends Neurosci, 28, 117-119. [CrossRef] [PubMed] [Google Scholar]
  • Baskin, A., Giannakopoulos, P., Ratib, O., Seimbille, Y., Assal, F., Perani, D., Garibotto, V. (2013). PET radiotracers for molecular imaging in dementia. Curr Radiopharm, 6, 215-230. [CrossRef] [PubMed] [Google Scholar]
  • Bernard-Gauthier, V., Collier, T.L., Liang, S.H., Vasdev, N. (2017). Discovery of PET radiopharmaceuticals at the academia-industry interface. Drug Discov Today Technol, 25, 19-26. [CrossRef] [PubMed] [Google Scholar]
  • Bernard-Gauthier, V., Lepage, M.L., Waengler, B., Bailey, J.J., Liang, S.H., Perrin, D.M., Vasdev, N., Schirrmacher, R. (2018). Recent advances in 18F Radiochemistry: A focus on B-18F, Si-18F, Al-18F, and C-18F radiofluorination via spirocyclic iodonium ylides. J Nucl Med, 59, 568-572. [CrossRef] [PubMed] [Google Scholar]
  • Billard, T., Liger, F., Verdurand, M., Serotonin receptor imaging by 18F-PET, in: G. Haufe, F. Leroux (Eds.), Fluorine in life sciences: Pharmaceuticals, medicinal diagnostics, and agrochemicals, Elsevier Sci., London, 2018, pp. 459-518. [Google Scholar]
  • Bloom, G.S. (2014). Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol, 71, 505-508. [Google Scholar]
  • Cai, L., Lu, S., Pike, V.W. (2008). Chemistry with [18F]fluoride ion. Eur J Org Chem, 17, 2853-2873. [CrossRef] [Google Scholar]
  • Casteels, C., Lauwers, E., Bormans, G., Baekelandt, V., Van Laere, K. (2008). Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease. Eur J Nucl Med Mol Imaging, 35, 124-134. [PubMed] [Google Scholar]
  • Chauveau, F., Boutin, H., Van Camp, N., Dollé, F., Tavitian, B. (2008). Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging, 35, 2304-2319. [PubMed] [Google Scholar]
  • Chételat, G. (2018). Multimodal neuroimaging in Alzheimer’s disease: Early diagnosis, physiopathological mechanisms, and impact of lifestyle. J Alzheimers Dis, 64, S199-S211. [CrossRef] [PubMed] [Google Scholar]
  • Chopra, A., Shan, L., Eckelman, W.C., Leung, K., Latterner, M., Bryant, S.H., Menkens, A. (2012). Molecular Imaging and Contrast Agent Database (MICAD): Evolution and progress. Mol Imaging Biol, 14, 4-13. [Google Scholar]
  • Colom, M., Costes, N., Redouté, J., Dailler, F., Gobert, F., Le Bars, D., Billard, T., Newman-Tancredi, A., Zimmer, L. (2019). 18F-F13640 PET imaging of functional receptors in humans. Eur J Nucl Med Mol Imaging, 2019. DOI: 10.1007/s00259-019-04473-7. [Google Scholar]
  • Cross, S., Cruciani, G. (2010). Molecular fields in drug discovery: Getting old or reaching maturity? Drug Discov Today, 15, 23-32. [CrossRef] [PubMed] [Google Scholar]
  • Cumming, P., Wong, D.F., Dannals, R.F., Gillings, N., Hilton, J., Scheffel, U., Gjedde, A. (2002). The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci, 965, 440-450. [CrossRef] [PubMed] [Google Scholar]
  • Eckelman, W.C., Jones, A.G., Duatti, A., Reba, R.C. (2013). Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites. Drug Discov Today, 18, 984-991. [CrossRef] [PubMed] [Google Scholar]
  • Egerton, A., Shotbolt, J.P., Stokes, P.R., Hirani, E., Ahmad, R., Lappin, J.M., Reeves, S.J., Mehta, M.A., Howes, O.D., Grasby, P.M. (2010). Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. Neuroimage, 50, 260-266. [CrossRef] [PubMed] [Google Scholar]
  • Elsinga, P.H., Hatano, K., Ishiwata, K. (2006). PET tracers for imaging of the dopaminergic system. Curr Med Chem, 13, 2139-2153. [CrossRef] [PubMed] [Google Scholar]
  • Emerit, M.B., El Mestikawy, S., Gozlan, H., Rouot, B., Hamon, M. (1990). Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins. Biochem Pharmacol, 39, 7-18. [CrossRef] [PubMed] [Google Scholar]
  • Engler, H., Damian, A., Bentancourt, C. (2015). PET and the multitracer concept in the study of neurodegenerative diseases. Dement Neuropsychol, 9, 343-349. [Google Scholar]
  • Farde, L., Plavén-Sigray, P., Borg, J., Cervenka, S. (2018). Brain neuroreceptor density and personality traits: Towards dimensional biomarkers for psychiatric disorders. Phil Trans R Soc B, 373, 1744. [CrossRef] [Google Scholar]
  • Ferris, S.H., de Leon, M.J., Wolf, A.P., Farkas, T., Christman, D.R., Reisberg, B., Fowler, J.S., Macgregor, R., Goldman, A., George, A.E., Rampal, S. (1980). Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging, 1, 127-131. [Google Scholar]
  • Finnema, S.J., Scheinin, M., Shahid, M., Lehto, J., Borroni, E., Bang-Andersen, B., Sallinen, J., Wong, E., Farde, L., Halldin, C., Grimwood, S. (2015). Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology (Berl), 232, 4129-4157. [CrossRef] [PubMed] [Google Scholar]
  • Fodero-Tavoletti, M.T., Okamura, N., Furumoto, S., Mulligan, R.S., Connor, A.R., McLean, C.A., Cao, D., Rigopoulos, A., Cartwright, G.A., O’Keefe, G., Gong, S., Adlard, P.A., Barnham, K.J., Rowe, C.C., Masters, C.L., Kudo, Y., Cappai, R., Yanai, K., Villemagne, V.L. (2011). 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer’s disease. Brain, 134, 1089-1100. [CrossRef] [PubMed] [Google Scholar]
  • Fowler, J.S., Wolf, A.P. (1997). Working against time: Rapid radiotracer synthesis and imaging the human brain. Accounts Chem Res, 30, 181-188. [CrossRef] [Google Scholar]
  • Fromm, M.F. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci, 25, 423-429. [Google Scholar]
  • Gao, Y., Tan, L., Yu, J.T., Tan, L. (2018). Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies. Curr Alzheimer Res, 15, 283-300. [CrossRef] [PubMed] [Google Scholar]
  • Ginovart, N. (2005). Imaging the dopamine system with in vivo [11C]raclopride displacement studies: Understanding the true mechanism. Mol Imaging Biol, 7, 45-52. [Google Scholar]
  • Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell, 140, 918-934. [CrossRef] [PubMed] [Google Scholar]
  • Gunn, R.N., Rabiner, E.A. (2017). Imaging in central nervous system drug discovery. Semin Nucl Med, 47, 89-98. [CrossRef] [PubMed] [Google Scholar]
  • Halldin, C., Gulyás, B., Langer, O., Farde L. (2001). Brain radioligands – state of the art and new trends. Q J Nucl Med, 45, 139-152. [PubMed] [Google Scholar]
  • Heiss, W.D., Herholz, K. (2006). Brain receptor imaging. J Nucl Med, 47, 302-312. [PubMed] [Google Scholar]
  • Herholz, K. (2010). Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease. Expert Rev Neurother, 10, 1667-1673. [CrossRef] [PubMed] [Google Scholar]
  • Herholz, K., Ebmeier, K. (2011). Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol, 10, 667-670. [CrossRef] [PubMed] [Google Scholar]
  • Iaccarino, L., Moresco, R.M., Presotto, L., Bugiani, O., Iannaccone, S., Giaccone, G., Tagliavini, F., Perani, D. (2018). An in vivo 11C-(R)-PK11195 PET and in vitro pathology study of microglia activation in Creutzfeldt-Jakob disease. Mol Neurobiol, 55, 2856-2868. [CrossRef] [PubMed] [Google Scholar]
  • Ikoma, Y., Takano, A., Ito, H., Kusuhara, H., Sugiyama, Y., Arakawa, R., Fukumura, T., Nakao, R., Suzuki, K., Suhara, T. (2006). Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med, 47, 1531-1537. [PubMed] [Google Scholar]
  • Jaffer, F.A., Weissleder, R. (2005). Molecular imaging in the clinical arena. JAMA, 293, 855-862. [CrossRef] [PubMed] [Google Scholar]
  • Jovalekic, A., Bullich, S., Catafau, A., de Santi, S. (2016). Advances in Aβ plaque detection and the value of knowing: Overcoming challenges to improving patient outcomes in Alzheimer’s disease. Neurodegener Dis Manag, 6, 491-497. [CrossRef] [PubMed] [Google Scholar]
  • Kadir, A., Nordberg, A. (2010). Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med, 51, 1418-1430. [CrossRef] [PubMed] [Google Scholar]
  • Kannan, P., John, C., Zoghbi, S.S., Halldin, C., Gottesman, M.M., Innis, R.B., Hall, M.D. (2009). Imaging the function of P-glycoprotein with radiotracers: Pharmacokinetics and in vivo applications. Clin Pharmacol Ther, 86, 368-377. [CrossRef] [PubMed] [Google Scholar]
  • Kapur, S., Phillips, A.G., Insel, T.R. (2012). Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry, 17, 1174-1179. [CrossRef] [PubMed] [Google Scholar]
  • Kennedy, R.T. (2013). Emerging trends in in vivo neurochemical monitoring by microdialysis. Curr Opin Chem Biol, 1, 860-867. [Google Scholar]
  • Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausén, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Långström, B. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol, 55, 306-319. [CrossRef] [PubMed] [Google Scholar]
  • Kobilka, B. (1992). Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci, 15, 87-114. [CrossRef] [PubMed] [Google Scholar]
  • Lacasse, J.R., Leo J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med, 2, e392. [CrossRef] [PubMed] [Google Scholar]
  • Lancelot, S., Zimmer, L. (2010). Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci, 31, 411-417. [Google Scholar]
  • Lane, C.A., Hardy, J., Schott, J.M. (2018). Alzheimer’s disease. Eur J Neurol, 25, 59-70. [CrossRef] [PubMed] [Google Scholar]
  • Laruelle, M. (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab, 20, 423-451. [CrossRef] [PubMed] [Google Scholar]
  • Lee, G., Bendayan, R. (2004). Functional expression and localization of P-glycoprotein in the central nervous system: Relevance to the pathogenesis and treatment of neurological disorders. Pharm Res, 21, 1313-1330. [CrossRef] [PubMed] [Google Scholar]
  • Ma, Y., Tang, C., Chaly, T., Greene, P., Breeze, R., Fahn, S., Freed, C., Dhawan, V., Eidelberg, D. (2010). Dopamine cell implantation in Parkinson’s disease: Long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med, 51, 7-15. [CrossRef] [PubMed] [Google Scholar]
  • Magistretti, P.J., Pellerin, L. (1996). The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry, 1, 445-452. [PubMed] [Google Scholar]
  • Man, S., Ubogu, E.E., Ransohoff, R.M. (2007). Inflammatory cell migration into the central nervous system: A few new twists on an old tale. Brain Pathol, 17, 243-250. [CrossRef] [PubMed] [Google Scholar]
  • Miller, P.W., Long, N.J., Vilar, R., Gee, A.D. (2008). Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed, 47, 8998-9033. [CrossRef] [Google Scholar]
  • Mongeau, R., Welner, S.A., Quirion, R., Suranyi-Cadotte, B.E. (1992). Further evidence for differential affinity states of the serotonin 1A receptor in rat hippocampus. Brain Res, 590, 229-238. [CrossRef] [PubMed] [Google Scholar]
  • Narendran, R., Martinez, D. (2008). Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature. Synapse, 62, 851-869. [CrossRef] [PubMed] [Google Scholar]
  • Nénonéné, E.K., Radja, F., Carli, M., Grondin, L., Reader, T.A. (1994). Heterogeneity of cortical and hippocampal 5-HT1A receptors: A reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin. J Neurochem, 62, 1822-1834. [PubMed] [Google Scholar]
  • Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., Kudo, Y. (2018). The development and validation of tau PET tracers: Current status and future directions. Clin Transl Imaging, 6, 305-316. [CrossRef] [PubMed] [Google Scholar]
  • Pagano, G., Niccolini, F., Politis, M. (2016). Imaging in Parkinson’s disease. Clin Med (Lond), 16, 371-375. [CrossRef] [PubMed] [Google Scholar]
  • Paterson, L.M., Tyacke, R.J., Nutt, D.J., Knudsen, G.M. (2010). Measuring endogenous 5-HT release by emission tomography: Promises and pitfalls. J Cereb Blood Flow Metab, 30, 1682-1706. [CrossRef] [PubMed] [Google Scholar]
  • Pellerin, L., Bouzier-Sore, A.K., Aubert, A., Serres, S., Merle, M., Costalat, R., Magistretti, P.J. (2007). Activity-dependent regulation of energy metabolism by astrocytes: An update. Glia, 55, 1251-1262. [CrossRef] [PubMed] [Google Scholar]
  • Phelps, M.E. (2000). Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A, 97, 9226-9233. [CrossRef] [PubMed] [Google Scholar]
  • Phelps, M.E., Mazziotta, J.C. (1995). Positron emission tomography: Human brain function and biochemistry. Science, 228, 799-809. [Google Scholar]
  • Pichler, V., Berroterán-Infante, N., Philippe, C., Vraka, C., Klebermass, E.M., Balber, T., Pfaff, S., Nics, L., Mitterhauser, M., Wadsak, W. (2018). An overview of PET radiochemistry, part 1: The covalent labels 18F, 11C, and 13N. J Nucl Med, 59, 1350-1354. [CrossRef] [PubMed] [Google Scholar]
  • Pien, H.H., Fischman, A.J., Thrall, J.H., Sorensen, A.G. (2005). Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today, 10, 259-266. [CrossRef] [PubMed] [Google Scholar]
  • Pike, V.W. (2009). PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci, 30, 431-440. [Google Scholar]
  • Recasens, A., Ulusoy, A., Kahle, P.J., Di Monte, D.A., Dehay, B. (2018). In vivo models of alpha-synuclein transmission and propagation. Cell Tissue Res, 373, 183-193. [Google Scholar]
  • Rees, G., Howseman, A., Josephs, O., Frith, C.D., Friston, K.J., Frackowiak, R.S.J., Turner, R. (1997). Characterizing the relationship between BOLD contrast and regional cerebral blood flow measurements by varying the stimulus presentation rate. NeuroImage, 6, 270-278. [CrossRef] [PubMed] [Google Scholar]
  • Reynolds, F., Kelly, K.A. (2011). Techniques for molecular imaging probe design. Mol Imaging, 10, 407-419. [CrossRef] [PubMed] [Google Scholar]
  • Rice, L., Bisdas, S. (2017). The diagnostic value of FDG and amyloid PET in Alzheimer’s disease – A systematic review. Eur J Radiol, 94, 16-24. [CrossRef] [PubMed] [Google Scholar]
  • Sawamoto, N., Piccini, P., Hotton, G., Pavese, N., Thielemans, K., Brooks, D.J. (2008). Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain, 131, 1294-1302. [CrossRef] [PubMed] [Google Scholar]
  • Scarf, A.M, Kassiou, M. (2011). The translocator protein. J Nucl Med, 52, 677-680. [CrossRef] [PubMed] [Google Scholar]
  • Schain, M., Kreisl, W.C. (2017). Neuroinflammation in neurodegenerative disorders – A Review. Curr Neurol Neurosci Rep, 17, 25. [CrossRef] [PubMed] [Google Scholar]
  • Schirrmacher, R., Wängler, B., Bailey, J., Bernard-Gauthier, V., Schirrmacher, E., Wängler, C. (2017). Small prosthetic groups in 18F-radiochemistry: Useful auxiliaries for the design of 18F-PET tracers. Semin Nucl Med, 47, 474-492. [CrossRef] [PubMed] [Google Scholar]
  • Schreiber, G., Avissar, S. (2007). Regulators of G-protein-coupled receptor-G-protein coupling: Antidepressants mechanism of action. Expert Rev Neurother, 7, 75-84. [CrossRef] [PubMed] [Google Scholar]
  • Schweitzer, P.J., Fallon, B.A., Mann, J.J., Kumar, J.S. (2010). PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discov Today, 21-22, 933-942. [Google Scholar]
  • Schwochau, K. (1994). Technetium radiopharmaceuticals – Fundamentals, synthesis, structure, and development. Angew Chem Int Ed, 33, 2258-2267. [CrossRef] [Google Scholar]
  • Seeman, P., Guan, H.C., Niznik, H.B. (1989). Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse, 3, 96-97. [CrossRef] [PubMed] [Google Scholar]
  • Shabab, T., Khanabdali, R., Moghadamtousi, S.Z., Kadir, H.A., Mohan, G. (2017). Neuroinflammation pathways: A general review. Int J Neurosci, 127, 624-633. [Google Scholar]
  • Shih, Y.Y., Wey, H.Y., De La Garza, B.H., Duong, T.Q. (2011). Striatal and cortical BOLD, blood flow, blood volume, oxygen consumption, and glucose consumption changes in noxious forepaw electrical stimulation. J Cereb Blood Flow Metab, 31, 832-841. [CrossRef] [PubMed] [Google Scholar]
  • Soares, J.C., Innis, R.B. (1999). Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry, 46, 600-615. [CrossRef] [PubMed] [Google Scholar]
  • Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M.H., Patlak, C.S., Pettigrew, K.D., Sakurada, O., Shinohara, M. (1977). The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem, 28, 897-916. [CrossRef] [PubMed] [Google Scholar]
  • Taddei, C., Gee, A.D. (2018). Recent progress in [11C]carbon dioxide ([11C]CO2) and [11C]carbon monoxide ([11C]CO) chemistry. J Labelled Comp Radiopharm, 61, 237-251. [Google Scholar]
  • Thathiah, A., De Strooper, B. (2011). The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci, 12, 73-87. [CrossRef] [PubMed] [Google Scholar]
  • Tournier, N., Bauer, M., Pichler, V., Nics, L., Klebermass, E.M., Bamminger, K., Matzneller, P., Weber, M., Karch, R., Caillé, F., Auvity, S., Marie, S., Jäger, W., Wadsak, W., Hacker, M., Zeitlinger, M., Langer O. (2019). Impact of P-glycoprotein function on the brain kinetics of the weak substrate 11C-metoclopramide assessed with PET imaging in humans. J Nucl Med, 60, 985-991. [CrossRef] [PubMed] [Google Scholar]
  • Tse, K.H., Herrup, K. (2017). Re-imagining Alzheimer’s disease – The diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem, 143, 432-444. [CrossRef] [PubMed] [Google Scholar]
  • Tyacke, R.J., Nutt, D.J. (2015). Optimising PET approaches to measuring 5-HT release in human brain. Synapse, 69, 505-511. [CrossRef] [PubMed] [Google Scholar]
  • van Gool, A.J., Henry, B., Sprengers, E.D. (2010). From biomarker strategies to biomarker activities and back. Drug Discov Today, 15, 121-126. [CrossRef] [PubMed] [Google Scholar]
  • Venneti, S., Lopresti, B.J., Wiley, C.A. (2006). The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: From pathology to imaging. Prog Neurobiol, 80, 308-322. [CrossRef] [PubMed] [Google Scholar]
  • Verbruggen, A., Coenen, H.H., Deverre, R., Guilloteau, D., Langstrom, B., Salvadori, P.A., Halldin, C. (2008). Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging, 35, 2144-2151. [Google Scholar]
  • Verdurand, M., Levigoureux, E., Zeinyeh, W., Berthier, L., Mendjel-Herda, M., Cadarossanesaib, F., Bouillot, C., Iecker, T., Terreux, R., Lancelot, S., Chauveau, F., Billard, T., Zimmer, L. (2018). In silico, in vitro, and in vivo evaluation of new candidates for α-synuclein PET imaging. Mol Pharm, 15, 3153-3166. [CrossRef] [PubMed] [Google Scholar]
  • Vernon, A.C., Ballard, C., Modo, M. (2010). Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Brain Res Rev, 65, 28-55. [CrossRef] [PubMed] [Google Scholar]
  • Vidal, B., Sebti, J., Verdurand, M., Fieux, S., Billard, T., Streichenberger, N., Troakes, C., Newman-Tancredi, A., Zimmer, L. (2016). Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer’s disease: A post-mortem study with PET radiopharmaceuticals. Neuropharmacology, 109, 88-95. [CrossRef] [PubMed] [Google Scholar]
  • Vidal, B., Fieux, S., Colom, M., Billard, T., Bouillot, C., Barret, O., Constantinescu, C., Tamagnan, G., Newman-Tancredi, A., Zimmer, L. (2018). 18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging. Brain Struct Funct, 223, 2973-2988. [Google Scholar]
  • Villar-Piqué, A., Lopes da Fonseca, T., Outeiro, T.F. (2016). Structure, function and toxicity of alpha-synuclein: The Bermuda triangle in synucleinopathies. J Neurochem, 139, 240-255. [CrossRef] [PubMed] [Google Scholar]
  • Volkow, N.D., Wiers, C.E., Shokri-Kojori, E., Tomasi, D., Wang, G.J., Baler, R. (2017). Neurochemical and metabolic effects of acute and chronic alcohol in the human brain: Studies with positron emission tomography. Neuropharmacology, 122, 175-188. [CrossRef] [PubMed] [Google Scholar]
  • Wager, T.T., Galatsis, P., Chandrasekaran, R.Y., Butler, T.W., Li, J., Zhang, L., Mente, S., Subramanyam, C., Liu, S., Doran, A.C., Chang, C., Fisher, K., Grimwood, S., Hedde, J.R., Marconi, M., Schildknegt, K. (2017). Identification and profiling of a selective and brain penetrant radioligand for in vivo target occupancy measurement of casein kinase 1 (CK1) inhibitors. ACS Chem Neurosci, 8, 1995-2004. [PubMed] [Google Scholar]
  • Wagner, C.C., Langer, O. (2011). Approaches using molecular imaging technology – use of PET in clinical microdose studies. Adv Drug Deliv Rev, 63, 539-546. [CrossRef] [PubMed] [Google Scholar]
  • Wagner, H.N. Jr, Burns, H.D., Dannals, R.F., Wong, D.F., Langstrom, B., Duelfer, T., Frost, J.J., Ravert, H.T., Links, J.M., Rosenbloom, S.B., Lukas, S.E., Kramer, A.V., Kuhar, M.J. (1983). Imaging dopamine receptors in the human brain by positron tomography. Science, 221, 1264-1266. [Google Scholar]
  • Wimo, A., Winblad, B., Aguero-Torres, H., von Strauss, E. (2003). The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord, 17, 63-67. [Google Scholar]
  • Zimmer, L. (2016). Pharmacological agonists for more-targeted CNS radiopharmaceuticals. Oncotarget, 7, 80111-80112. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.